AMIGRAF

AMIGRAF (Tacrolimus) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient’s immune system and so the risk of organ rejection. Tacrolimus is used together with other medicines in people who have had a heart, kidney, liver, or lung transplant. Tacrolimus weakens immune system to prevent the body from “rejecting” the transplanted organ.

COMPOSITION:

Tacrolimus Capsules 0.25 mg, 0.5 mg, 1 mg & 2 mg

MODE OF ACTION:

Tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines.

INDICATIONS

• Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants.
• Treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants.

DOSAGE

Usual initial dosage: 200 mcg/kg (0.2 mg/kg) daily, administered in 2 divided doses every 12 hours. Therapy may be administered within 24 hours of kidney transplantation, but should be delayed until renal function has recovered (e.g., Scr ≤4 mg/dL).

STORAGE

Store at room temperature not exceeding 25ᵒC.

DISCLAIMER

This information is for the medical professionals & registered medical practitioners only. This product must be consumed with the valid prescription of registered medical practitioners.